去纤苷的不良反应有什么呢？

It is a polydeoxyribose ribonate with certain fibrinolytic and anti-thrombotic activities, which can promote the production of prostacyclin-like substances and release them from vascular tissues into the circulation.

Defibrotide is used to treat adult and pediatric patients with hepatic venous occlusion (VOD) and renal or pulmonary abnormalities after blood or bone marrow hematopoietic stem cell transplantation (HSCT). What are the adverse effects of defibrotide?

The most common adverse reactions (incidence ≥10% and independent causal relationship) of defibrotide are hypotension, diarrhea, vomiting, nausea and epistaxis.

In addition to paying attention to adverse reactions when using defibrotide, you should also pay attention to the following precautions:

1. Defibrotide needs to be administered by injection, and defibrotide must be diluted before infusion.

2. Before administration of defibrotide, confirm that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressor.

3. Do not co-administer defibrotide and other intravenous drugs in the same intravenous line at the same time.

4. Bleeding: Monitor the patient for bleeding. If significant bleeding occurs, withhold or discontinue defibrotide.

5. Hypersensitivity reaction: If a severe or life-threatening allergic reaction occurs, discontinue defibrination, treat according to standard medical care, and monitor until signs and symptoms resolve.

Contraindications: Concomitant administration with systemic anticoagulants or fibrinolytic therapy. Known hypersensitivity to defibrotide or to any of the excipients.

Recommended dose of defibrotide: 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days.

If signs and symptoms of hepatic venule occlusion do not resolve after 21 days, continue until resolution of hepatic venule occlusion or up to a maximum of 60 days.

Recommended related hot articles: /newsDetail/75013.html